Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Infections and infestations – page 15

  • 686 clinical trials
  • 263 recruiting
  • 279 conditions
  • 27 countries

Conditions in this area

279 conditions with trials, the busiest first

HIV infection78COVID-1939Pneumonia32Influenza29Sepsis29Respiratory syncytial virus infection20Post-acute COVID-19 syndrome19Urinary tract infection19Septic shock17Chronic hepatitis B16Bacterial infection14Hepatitis D14Cytomegalovirus infection13Appendicitis10Hepatitis B10Pneumonia bacterial10Fungal infection9Irritable bowel syndrome8Medical device site joint infection8Pyelonephritis acute7Staphylococcal bacteraemia7Staphylococcal infection7T-cell type acute leukaemia7Lower respiratory tract infection6+255

Clinical trials in Infections and infestations

686 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

686 clinical trials

Sepsis

Recruiting

Study on Optimizing Initial Dosing of Flucloxacillin and Drug Combination for Critically Ill Patients with Sepsis in the ICU

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Irritable bowel syndrome

Recruiting

Study on the Effectiveness and Safety of Myrrh, Coffee Charcoal, and Chamomile Extract for Patients with Diarrhea-Dominant or Mixed-Type Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Coffee Charcoal
  • Sponsor:REPHA GmbH Biologische Arzneimittel

Epstein-Barr virus associated lymphoproliferative disorder

Recruiting

Study on Tabelecleucel for Patients with Epstein-Barr Virus-Associated Diseases

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Irritable bowel syndrome

Recruiting

Study on the Effectiveness and Safety of Myrrh, Coffee Charcoal, and Chamomile Extract for Patients with Diarrhea-Predominant Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Coffee Charcoal
  • Sponsor:REPHA GmbH Biologische Arzneimittel

Staphylococcal infection+1

Recruiting

Study on the Safety of Inhaled Teicoplanin for Treating Staphylococcus aureus Infections in Cystic Fibrosis Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Teicoplanin
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Cytomegalovirus infection+1

Recruiting

Study on Letermovir for Preventing Cytomegalovirus in Stem Cell Transplant Patients with CMV-Positive Donors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Letermovir

Clostridium difficile infection

Recruiting

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Mycobacterium avium complex infection

Recruiting

Study Comparing Clarithromycin and Azithromycin for Treating Mycobacterium Avium Complex Lung Infections in Adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Kawasaki's disease

Recruiting

Comparing Anakinra versus Immunoglobulin for Treatment-Resistant Kawasaki Disease in Patients Who Failed Initial Immunoglobulin Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:Assistance Publique Hopitaux De Paris

Septic shock

Recruiting

A Study of Levetiracetam for Prevention and Treatment of Delirium in Adult ICU Patients with Septic Shock

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Levetiracetam
  • Sponsor:Assistance Publique Hopitaux De Paris

Septic shock

Recruiting

Study on the Effectiveness and Safety of IgM-Enriched Immunoglobulin Therapy for Patients with Septic Shock

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Immunoglobulin A
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Septic shock

Recruiting

Study on the Effects of Sodium Lactate and Saline Solutions in Patients with Septic Shock

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Lactate
  • Sponsor:Fakultni Nemocnice Plzen

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Sodium Chloride52 clinical trialsAmoxicillin35 clinical trialsEmtricitabine33 clinical trialsTenofovir Alafenamide33 clinical trialsLinezolid32 clinical trialsClavulanic Acid28 clinical trialsRifampicin25 clinical trialsSulfamethoxazole25 clinical trialsTrimethoprim25 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.